- Home
- FET vs ELDN Comparison
FET vs ELDN Comparison
Compare FET & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FET
- ELDN
- Stock Information
- Founded
- FET 2005
- ELDN 2004
- Country
- FET United States
- ELDN United States
- Employees
- FET N/A
- ELDN N/A
- Industry
- FET Metal Fabrications
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- FET Industrials
- ELDN Health Care
- Exchange
- FET Nasdaq
- ELDN Nasdaq
- Market Cap
- FET 240.1M
- ELDN 178.4M
- IPO Year
- FET 2012
- ELDN N/A
- Fundamental
- Price
- FET $20.66
- ELDN $3.19
- Analyst Decision
- FET
- ELDN Strong Buy
- Analyst Count
- FET 0
- ELDN 2
- Target Price
- FET N/A
- ELDN $12.50
- AVG Volume (30 Days)
- FET 80.2K
- ELDN 619.6K
- Earning Date
- FET 08-07-2025
- ELDN 08-18-2025
- Dividend Yield
- FET N/A
- ELDN N/A
- EPS Growth
- FET N/A
- ELDN N/A
- EPS
- FET N/A
- ELDN N/A
- Revenue
- FET $807,312,000.00
- ELDN N/A
- Revenue This Year
- FET N/A
- ELDN N/A
- Revenue Next Year
- FET $1.56
- ELDN N/A
- P/E Ratio
- FET N/A
- ELDN N/A
- Revenue Growth
- FET 7.31
- ELDN N/A
- 52 Week Low
- FET $12.78
- ELDN $2.38
- 52 Week High
- FET $21.57
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- FET 62.59
- ELDN 38.45
- Support Level
- FET $19.12
- ELDN $3.63
- Resistance Level
- FET $20.11
- ELDN $3.95
- Average True Range (ATR)
- FET 0.69
- ELDN 0.28
- MACD
- FET -0.03
- ELDN -0.07
- Stochastic Oscillator
- FET 75.47
- ELDN 10.97
About FET Forum Energy Technologies Inc.
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.